

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**CARTON**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

HY-50 Vet 17 mg/ml solution for injection  
Sodium hyaluronate

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

1 ml contains

**Active Substance**

Sodium hyaluronate	17 mg
--------------------	-------

**Excipients**

Sodium chloride	7.57 mg
Disodium phosphate heptahydrate	3.78 mg
Sodium dihydrogen phosphate monohydrate	0.45 mg
Water for injection	qs to 1 ml

**3. PHARMACEUTICAL FORM**

Solution for injection

**4. PACKAGE SIZE**

3 ml single-dose syringe  
12 x 3 ml single-dose syringes

**5. TARGET SPECIES**

Horse

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

For intra-articular and intravenous use in horses

**8. WITHDRAWAL PERIOD**

Meat and offal – zero days

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP

**11. SPECIAL STORAGE CONDITIONS**

Store in a refrigerator (2 °C – 8 °C).  
Do not freeze.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Dechra Limited  
Snaygill Industrial Estate, Keighley Road, Skipton, North Yorkshire, BD23 2RW  
United Kingdom

**16. MARKETING AUTHORISATION NUMBER(S)**

Vm: 10434/4078

**17. MANUFACTURER’S BATCH NUMBER**

Lot

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**  
**LABEL FOR SINGLE-DOSE SYRINGE**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

HY-50 Vet 17 mg/ml solution for injection  
Sodium hyaluronate

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

1 ml contains

**Active Substance**  
Sodium hyaluronate 17 mg

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

3 ml

**4. ROUTES OF ADMINISTRATION**

Intra-articular/intravenous administration.

**5. WITHDRAWAL PERIOD**

Withdrawal period: Meat and offal: Zero days.

**6. BATCH NUMBER**

Lot

**7. EXPIRY DATE**

EXP

**8. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only.

Target species: Horse.

## **B. PACKAGE LEAFLET**

**PACKAGE LEAFLET FOR:**

**HY-50 Vet 17 mg/ml solution for injection**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder:

Dechra Limited  
Snaygill Industrial Estate  
Keighley Road  
Skipton  
North Yorkshire  
BD23 2RW  
United Kingdom

Manufacturers responsible for the batch release:

Eurovet Animal Health B.V.  
Handelsweg 25  
5531 AE Bladel  
The Netherlands

Dales Pharmaceuticals Limited  
Snaygill Industrial Estate  
Keighley Road  
Skipton  
North Yorkshire  
BD23 2RW  
United Kingdom

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

HY-50 Vet 17 mg/ml solution for injection  
Sodium hyaluronate

**3. STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS**

1ml contains:

Active Substance:

Sodium hyaluronate 17 mg

Excipients:

Sodium chloride	7.57 mg
Disodium phosphate heptahydrate	3.78 mg
Sodium dihydrogen phosphate monohydrate	0.45 mg
Water for injection	qs to 1 ml

Sterile, colourless, clear solution.

#### **4. INDICATION(S)**

For intra-articular and intravenous treatment of lameness caused by joint dysfunction associated with non-infectious synovitis.

#### **5. CONTRAINDICATIONS**

Do not use in cases of joint infection.

#### **6. ADVERSE REACTIONS**

Transient mild swelling and/or heat has been reported in treated joints (2,7%). These self-limiting local signs resolve spontaneously within 48 hours, and do not negate a successful therapeutic outcome.

If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon.

#### **7. TARGET SPECIES**

Horse.

#### **8. DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION**

Intravenous use: 3 ml intravenously repeated at weekly intervals for a total of three treatments.

For single intra-articular injection: 3 ml (51 mg) intra-articularly into medium sized and large joints. Smaller joints such as intertarsal, tarsometatarsal and interphalangeal joints can be treated with a 1.5 ml (25.5 mg) dose.

More than one joint may be treated at the same time.

#### **9. ADVICE ON CORRECT ADMINISTRATION**

Excess synovial fluid should be removed whenever possible prior to injection.

Remove product from refrigerator approximately 10 minutes before performing injection. The injection should be administered under strict aseptic conditions. Ensure removal of dirt, hair, topical medicaments and soap/antiseptic residues. Intra-articular injections should not be made through overlying skin that is infected, blistered, scurfed or otherwise compromised. A sterile dressing and clean bandage should be applied after injection, as appropriate for the particular joint treated.

#### **10. WITHDRAWAL PERIOD**

Meat and offal – zero days



## 11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Store in a refrigerator (2 °C – 8 °C)  
Do not freeze

Do not use after the expiry date stated on the label and carton.

Single dose syringes made ready for injection shall be used immediately. Any unused portion of a syringe is to be discarded.

## 12. SPECIAL WARNINGS

Special precautions for use in animals:

Radiographic evaluation should be carried out in cases of acute, severe lameness to ensure that the joints are free from serious fractures.

Use during pregnancy and lactation:

Safety in pregnant and lactating mares has not been documented. Use only according to the benefit/risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction: No data available.  
Do not mix with any other product.

## 13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

## 14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

06/2019

## 15. OTHER INFORMATION

For animal treatment only. To be supplied only on veterinary prescription.

POM-V

Pack sizes:

3 ml single-dose syringe


12 x 3 ml single-dose syringes

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

Dechra Veterinary Products Limited , Sansaw Business Park, Hadnall, Shrewsbury, Shropshire, SY4 4AS, United Kingdom.

Approved: 18 June 2019

A handwritten signature in black ink, appearing to read 'J. King'.